Transfusion therapy and erythropoiesis-stimulating agents (ESAs)

ESH eLearning, Arjan van de Loosdrecht, 21288

Clinical evaluation and risk assessment in children and young adults

ESH eLearning, Charolotte Niemeyer, 21287

Less common clinical features in MDS

ESH eLearning, Eva Hellstrom-Lindberg, 21285

Clinical presentation including data from the EUMDS Registry

ESH eLearning, Theo De Witte, 21284

Cytogenetics and molecular genetics in clinical practice

ESH eLearning, Brigitte Schlegelberger, 21282

Immunophenotyping

ESH eLearning, Arjan van de Loosdrecht, 21281

Role of morphology in 2012

ESH eLearning, Anna Porwit, 21280

MDS stem and progenitor cell biology

ESH eLearning, Petter S. Woll, 21279

Deciphering myelodysplastic genome

ESH eLearning, Joop Jansen, 21276

Incidence of MDS and environmental factors

ESH eLearning, DT Bowen, 21274

Chapter 24 - Ethics of research and clinical practice

ESH eLearning, Cliff Chaplin, 165709

Chapter 23 - Cell therapy for tissue regeneration/repair

ESH eLearning, Eliane Gluckman Marie Caroline Le Bousse-Kerdi, 165708

Chapter 22 - Methodology of conducting academic clinical trials in Europe

ESH eLearning, M Mohty, 165707

Chapter 21 - Statistical evaluation of HSCT data

ESH eLearning, Richard Richard, 165706

Chapter 20.10 - High-dose chemotherapy and HSCT in children and adolescents with solid tumours in Europe

ESH eLearning, Ruth Ladenstein and Ulrike Pötschger, 165705

Chapter 20.9 - Haemoglobinopathies

ESH eLearning, Emanuele Angelucci and Donatella Baronciani, 165704

Chapter 20.8 - Hereditary bone marrow failure syndromes

ESH eLearning, eliane Gluckman, 165703

Chapter 20.7 - HSCT in inborn errors of metabolism and osteopetrosis

ESH eLearning, Jaap J. Boelens, Marc Bierings Robert Wynn, 165702

Chapter 20.6 - Primary immunodeficiency diseases

ESH eLearning, Paul Veys and H. Bobby Gaspar, 165701

Chapter 20.5 - HSCT for lymphomas in children and adolescents

ESH eLearning, Franco Claviez, 165700

Chapter 20.4 - Chronic myeloproliferative disorders: The role of HSCT in childhood MPD

ESH eLearning, Franco Locatelli and Charlotte M. Niemeyer, 165699

Chapter 20.3 - HSCT in children with myelodysplastic syndromes

ESH eLearning, Franco Locatelli Alice Bertaina, Giuseppe Palum, 165698

Chapter 20.2 -Acute lymphoblastic leukaemia in children and adolescents

ESH eLearning, Christina Peters, 165697

Chapter 20.1 - Acute myeloid leukaemia

ESH eLearning, Giorgio Dini and Stefano Giardino, 165696

Chapter 19.12 - Aplastic anaemia and paroxysmal nocturnal haemoglobinuria

ESH eLearning, Judith Marsh, 165695

Chapter 19.11 - Autoimmune diseases

ESH eLearning, John A. Snowden, Riccardo Sacc Dominique Farge, 165694

Chapter 19.10 - Solid tumours in adults

ESH eLearning, Marco Bregni, 165693

Chapter 19.9 - HSCT for Hodgkin’s lymphoma in adults

ESH eLearning, Anna Sureda and Harry C. Schouten, 165692

Chapter 19.8 - HSCT for non-Hodgkin’s lymphoma

ESH eLearning, Harry C. Schouten and Anna Sureda, 165691

Chapter 19.7 - Role of HSCT in primary amyloidosis

ESH eLearning, M. Teresa Cibeira and Jordi Esteve, 165690

Chapter 19.6 - Multiple myeloma

ESH eLearning, Jesús San-Miguel, José A. Pére M. Victoria Mateos, 165689

Chapter 19.5 - Chronic lymphocytic leukaemia

ESH eLearning, Peter Dreger and Johannes Schetelig, 165688

Chapter 19.4 - Chronic myeloid leukaemia and the myeloproliferative disorders

ESH eLearning, Jiri Pavlu and Jane Apperley, 165687

Chapter 19.3 - HSCT for myelodysplastic syndromes

ESH eLearning, Nicolaus Kröger, 165686

Chapter 19.2 - Acute lymphoblastic leukaemia

ESH eLearning, M Mohty, 165685

Chapter 19.1 - Acute myeloid leukaemia

ESH eLearning, M Mohty, 165684

Chapter 18 - Indications for and current practice of allogeneic and autologous HSCT

ESH eLearning, Alois Gratwohl, Helen Baldomer Anna Sureda, 165683

Chapter 17 – Immunotherapy post-transplant

ESH eLearning, Inge Jedema and J.H. Frederik Falkenburg, 165682

Chapter 16.2 - Chimerism

ESH eLearning, Thomas Lion, 165681

Chapter 16.1 - Molecular monitoring of minimal residual disease

ESH eLearning, Jean-Michel Cayuela, 165680

Chapter 15 - Late effects in patients treated with HSCT

ESH eLearning, Andre Tichelli, 165679

Chapter 14 - Immune reconstitution after allogeneic HSCT

ESH eLearning, Antoine Toubert, 165678

Chapter 13 - Graft-versus-host disease

ESH eLearning, Jane Apperley and Tamas Masszi, 165677

Chapter 12 - Infections after HSCT

ESH eLearning, Montserrat Rovira, Josep Mensa Enric Carreras, 165676

Chapter 11 - Early complications after HSCT

ESH eLearning, Enric Carreras, 165675

Chapter 10 - Supportive care

ESH eLearning, Tamas Masszi and Arno Mank, 165674

Chapter 9 - Transfusion support in patients undergoing HSCT

ESH eLearning, Rachel Pawson and Derwood Pamphilon, 165673

Chapter 8 - Principles of conditioning

ESH eLearning, Alois Gratwohl and Enric Carreras, 165672

Chapter 7 - Bone marrow donor registries and cord blood banks

ESH eLearning, Carlheinz Mueller and Sergio Querol, 165671

Chapter 6 - Choice of the donor according to HLA typing and stem cell source

ESH eLearning, eliane Gluckman, 165670

Chapter 5 - Immunogenetics of allogeneic HSCT

ESH eLearning, Bronwen E. Shaw Alejandro Madrigal, 165669

Chapter 4 - Biological properties of haematopoietic stem cells

ESH eLearning, Aleksandra Wodnar-Filipowicz, 165668

Chapter 3 - JACIE & quality management in HSCT

ESH eLearning, Christian Chabannon Eoin McGrath, 165667

Chapter 2 - Present and future

ESH eLearning, Alejandro Madrigal Anna Sureda, 165666

Chapter 1 - A brief history of HSCT

ESH eLearning, eliane Gluckman, 165665

Cord blood transplant and very rare anaemias

ESH eLearning, Annalisa Ruggeri, 17976

Quality controls for the diagnosis of rare red cell disorders

ESH eLearning, Andrea Mosca, 17974

Paroxysmal Nocturnal Haemoglobinuria

ESH eLearning, Regis Peffault de Latour, 17973

Microangiopathic haemolytic anaemias - TTP, HUS ( haemolytic uraemic syndrome)

ESH eLearning, Paul Coppo, 17972

Autoimmune haemolytic anaemias by warm antibodies

ESH eLearning, Norbert Ahrens, 17970

Cold-antibody mediated autoimmune hemolytic anemia

ESH eLearning, Sigbjorn Berentsen, 17971

Clinical case 3

ESH eLearning, Joan-LLuis Vives-Corrons, 17969

Clinical case 2

ESH eLearning, A. A. M. Ermens, 19900

Clinical Case 1

ESH eLearning, R van Wijk, 19899

Normal and defective red blood cell metabolism abnormalities of glycolysis and the generation of reduced glutathione

ESH eLearning, R van Wijk, 17968

Closing talk of Day 1

ESH eLearning, Joan-LLuis Vives-Corrons, 17967

Erythropoietic porphyrias

ESH eLearning, Jean Charles Deybach, 17966

Clinical cases of membrane disorders

ESH eLearning, Alberto Zanella & Leticia Ribeiro, 19868

Hereditary elliptocytosis, pyropoikilocytosis and South-East Asian Ovalocytosis

ESH eLearning, Leticia Ribeiro, 17963

Hereditary spherocytosis

ESH eLearning, Alberto Zanella, 17962

Iron overload and chelation therapy

ESH eLearning, Maria Domenica Cappellini, 19866

Clinical cases

ESH eLearning, Maria Domenica Cappellini, 17961

Hereditary sideroblastic anaemias

ESH eLearning, Alison May, 17960

Rare inherited anaemias due to defects in the erythroblastiron acquisition pathway

ESH eLearning, Carole Beaumont, 17959

What are very rare anaemias ?

ESH eLearning, GULBIS BEATRICE, 17954

Welcome to Participants

ESH eLearning, Patricia Aguilar-Martinez, 19865

Recurrent fetal loss and thrombophilia

ESH eLearning, Saskia Middeldorp, 17339

Novel antithrombotic drugs

ESH eLearning, Sylvia Haas, 17338

Disseminated intravascular coagulation

ESH eLearning, Marcel Levi, 17337

Antiphospholipid syndrome

ESH eLearning, Ph G. de Groot, 17335

Cancer and thrombosis

ESH eLearning, Anna Falanga, 17334

Arterial thrombosis, pathogenesis, epidemiology

ESH eLearning, Gordon Lowe, 17330

Venous Thrombosis: etiology, pathogenesis and prognosis

ESH eLearning, Frits Rosendaal, 17328

Genetic risk factors of arterial and venous thrombosis

ESH eLearning, Pieter Reitsma, 17327

Control Mechanisms of coagulation

ESH eLearning, Bjorn Dahlback, 17326

Inherited platelet bleeding disorders, diagnosis and treatment

ESH eLearning, Alan Nurden, 17325

Management of coagulation disorders, complications and prevention

ESH eLearning, Pier Mannucci, 17323

Rare Bleeding Disorders

ESH eLearning, Flora Peyvandi, 17322

Molecular genetics of coagulation

ESH eLearning, Pieter Reitsma, 17320

Biochemistry of the coagulation systems

ESH eLearning, David Lane, 17319

Stopping TKI can now be recommended in selected partients: no

ESH eLearning, Giuseppe Saglio, 12583

Stopping TKI can now be recommended in selected patients: yes

ESH eLearning, François-Xavier Mahon, 12581

Debate

ESH eLearning, Session Speakers, 12606

Maintenance of a stable CCyR is an adequate therapeutic target: no

ESH eLearning, Philippe Rousselot, 12585

Maintenance of a stable CCyR is an adequate therapeutic target: yes

ESH eLearning, Michele Baccarani, 12584

All CML patients should start treatment with 2G-TKI: no

ESH eLearning, charles schiffer, 12586

Residual normal stem cells can be detected in newly diagnosed CML patients by a new flow cytometric approach and predict for optimal response to imatinib

ESH eLearning, Jeroen Janssen, 12601

The Prognostic significance of Molecular and Cytogenetic response landmarks after 3 month of Imatinib in the upfront treatment of CML

ESH eLearning, Benjamin Hanfstein, 12598

Switching to nilotinib vs imatinib dose escalation for patients with suboptimal treatment response to imatinib: 24 month update of the TIDEL-II trial

ESH eLearning, David T Yeung, 12596

High BCR-ABLIS expression levels at diagnosis and after 3 and 6 months of treatment are associated with an unfavourable response to imatinib

ESH eLearning, Paolo Vigneri, 12597